---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-119756"
form_type: "8-K"
ticker: "MBIO"
cik: "0001680048"
company_name: "MUSTANG BIO, INC."
filed_at: "2024-11-15T23:59:59+00:00"
generated_at: "2026-05-29T23:49:11.292832+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Mustang Bio receives Nasdaq delist notice but granted extension; interim CFO resigns, CEO takes over

## Summary
- Nasdaq Staff issued delist determination on Nov 13, 2024 for non-compliance with bid price rule.
- Nasdaq Hearings Panel granted extension to Jan 31, 2025 for bid price and Feb 18, 2025 for equity rule compliance.
- James Murphy resigned as Interim CFO on Nov 12, 2024; no disagreement involved.
- President/CEO Manuel Litchman appointed Interim CFO effective Nov 15, 2024; previously held role in Dec 2023-Jan 2024.

## SEC filing metadata
- accession: 0001104659-24-119756
- form_type: 8-K
- ticker: MBIO
- cik: 0001680048
- company_name: MUSTANG BIO, INC.
- filed_at: 2024-11-15T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680048/000110465924119756/0001104659-24-119756-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680048/000110465924119756/tm2428644d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-119756
- JSON: https://secwatch.observer/filing/0001104659-24-119756.json
- Plain text: https://secwatch.observer/filing/0001104659-24-119756.txt

## Key facts
- Executive change
  James Murphy resigned as Interim Chief Financial Officer at MUSTANG BIO, INC..
  - Action: resigned
  - Role: Interim Chief Financial Officer
  source text: On November 12, 2024, James Murphy resigned as the Company’s Interim Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680048/000110465924119756/0001104659-24-119756-index.htm
- Executive change
  Manuel Litchman was appointed as Interim Chief Financial Officer at MUSTANG BIO, INC..
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: On November 15, 2024, the Company’s Board of Directors (the “Board”) appointed Manuel Litchman, M.D., President and Chief Executive Officer of the Company, as the Company’s Interim Chief Financial Officer, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680048/000110465924119756/0001104659-24-119756-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.